Generation Bio (GBIO) to Release Quarterly Earnings on Wednesday

Generation Bio (NASDAQ:GBIO) is projected to post its quarterly earnings results before the market opens on Wednesday, March 5th. Analysts expect Generation Bio to post earnings of ($0.31) per share and revenue of $2.92 million for the quarter.

Generation Bio Price Performance

GBIO opened at $0.54 on Tuesday. Generation Bio has a 12 month low of $0.53 and a 12 month high of $4.65. The business has a 50-day moving average of $0.84 and a two-hundred day moving average of $1.65. The stock has a market capitalization of $35.87 million, a price-to-earnings ratio of -0.25 and a beta of 2.69.

Insider Buying and Selling at Generation Bio

In other news, Director Anthony G. Quinn acquired 125,791 shares of Generation Bio stock in a transaction that occurred on Friday, January 10th. The shares were purchased at an average cost of $0.96 per share, for a total transaction of $120,759.36. Following the completion of the purchase, the director now directly owns 214,286 shares of the company’s stock, valued at $205,714.56. This trade represents a 142.14 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 21.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Wedbush restated an “outperform” rating and issued a $5.00 price target on shares of Generation Bio in a report on Thursday, November 7th. Needham & Company LLC cut their target price on shares of Generation Bio from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.